{
    "clinical_study": {
        "@rank": "102337", 
        "arm_group": [
            {
                "arm_group_label": "gabapentin", 
                "arm_group_type": "Active Comparator", 
                "description": "Neurotin"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Glycerin based clear solution that is flavored similar to the commercial product"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a prospective, randomized, double blind, placebo controlled, crossover\n      clinical trial looking at whether gabapentin can provide symptom relief for chronic\n      irritability in neurologically impaired children.  The investigators hypothesize gabapentin\n      ins beneficial and safe for children with chronic irritability that persists despite\n      identification and appropriate management of symptom sources."
        }, 
        "brief_title": "Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neurologically Impaired", 
            "Irritable Mood", 
            "Signs and Symptoms, Digestive", 
            "Sleeplessness", 
            "Chronic Pain"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Signs and Symptoms", 
                "Signs and Symptoms, Digestive", 
                "Sleep Initiation and Maintenance Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, placebo-controlled, cross-over study design of the effects of\n      gabapentin on chronic irritability in neurologically impaired children.  The study will\n      involve a 22 day medication titration, followed by a 7 day stable dosing period and a 6 day\n      medication taper period.  After an additional 3 day washout period, the subject will\n      cross-over to the remaining arm of the study.  Subjects will be evaluated for symptoms of\n      chronic pain.  Since the subjects are generally non-communicative, the subjects will be\n      evaluated by two questionnaires and the Non-Communicating Children's Pain Checklist-Revised,\n      to be completed by their parent or primary caregiver.\n\n      The primary aim is to determine if gabapentin provides symptom relief for chronic\n      irritability in neurologically impaired children."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  male or female\n\n          -  1 month to 16 years of age at enrollment\n\n          -  neurological impairment defined as subnormal (-2 S.D.) motor and/or cognitive ability\n             from a variety of etiologies\n\n          -  chronic irritability defined as symptoms suggesting pain to the child's caregiver\n             recurrently over a 4-week of greater time period\n\n          -  Subject must have an acceptable surrogate capable of giving consent on the subject's\n             behalf\n\n        Exclusion Criteria:\n\n          -  Children with resolved symptoms after treatment of identified sources of pain\n\n          -  Identified potential source of irritability without adequate trial of appropriate\n             management\n\n          -  Ketogenic diet\n\n          -  Renal insufficiency or failure\n\n          -  Current treatment with gabapentin or pregabalin for another existing condition."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "16 Years", 
            "minimum_age": "1 Month"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01675960", 
            "org_study_id": "112909"
        }, 
        "intervention": [
            {
                "arm_group_label": "gabapentin", 
                "description": "The active drug is in a flavored glycerin based solution.  The drug will be given orally or through a gastrointestinal tube.  Titration up to a stable dose will take 22 days.  The total stable dose is 40mg/kg/day. Once 7 days on this dose are finished, children will take 6 days to reduce their dose and begin their 3 day washout period.", 
                "intervention_name": "Gabapentin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Fanatrex", 
                    "Neurontin", 
                    "Gabarone", 
                    "Gralise", 
                    "Horizant"
                ]
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Gabapentin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "chronic irritability", 
            "chronic pain", 
            "Neurologically impaired", 
            "gabapentin"
        ], 
        "lastchanged_date": "October 24, 2013", 
        "location": {
            "contact": {
                "email": "KariAWilliams@gillettechildrens.com", 
                "last_name": "Kari A Williams, MPH, CCRC", 
                "phone": "651-325-2316"
            }, 
            "contact_backup": {
                "email": "sschwantes@gillettechildrens.com", 
                "last_name": "Scott Schwantes, MD", 
                "phone": "651-229-3818"
            }, 
            "facility": {
                "address": {
                    "city": "St. Paul", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55101"
                }, 
                "name": "Gillette Children's Specialty Healthcare"
            }, 
            "investigator": {
                "last_name": "Scott Schwantes, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II, Randomized, Placebo-controlled, Double Blind, Cross-over, Study of the Effects of Gabapentin on Chronic Irritability in Neurologically Impaired Children", 
        "overall_contact": {
            "email": "KariAWilliams@gillettechildrens.com", 
            "last_name": "Kari A Williams, MPH, CCRC", 
            "phone": "651-325-2316"
        }, 
        "overall_contact_backup": {
            "email": "sschwantes@gillettechildrens.com", 
            "last_name": "Scott Schwantes, MD", 
            "phone": "651-229-3818"
        }, 
        "overall_official": {
            "affiliation": "Gillette Children's Specialty Healthcare", 
            "last_name": "Scott Schwantes, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We will determine whether gabapentin provides symptom relief for chronic irritability in neurologically impaired children, who continue to have irritability even though potential sources may have been identified and treated, or have sources that have not been identified.", 
            "measure": "Symptom relief for chronic irritability in neurologically impaired children using gabapentin.", 
            "safety_issue": "No", 
            "time_frame": "Compiled data reviewed at completion or withdrawal from study (3 months from beginning study)."
        }, 
        "reference": [
            {
                "PMID": "10863045", 
                "citation": "Perquin CW, Hazebroek-Kampschreur AA, Hunfeld JA, Bohnen AM, van Suijlekom-Smit LW, Passchier J, van der Wouden JC. Pain in children and adolescents: a common experience. Pain. 2000 Jul;87(1):51-8."
            }, 
            {
                "PMID": "14662579", 
                "citation": "Breau LM, Camfield CS, McGrath PJ, Finley GA. The incidence of pain in children with severe cognitive impairments. Arch Pediatr Adolesc Med. 2003 Dec;157(12):1219-26."
            }, 
            {
                "PMID": "15132260", 
                "citation": "Houlihan CM, O'Donnell M, Conaway M, Stevenson RD. Bodily pain and health-related quality of life in children with cerebral palsy. Dev Med Child Neurol. 2004 May;46(5):305-10."
            }, 
            {
                "PMID": "11719327", 
                "citation": "Stallard P, Williams L, Lenton S, Velleman R. Pain in cognitively impaired, non-communicating children. Arch Dis Child. 2001 Dec;85(6):460-2."
            }, 
            {
                "PMID": "16009254", 
                "citation": "Greco C, Berde C. Pain management for the hospitalized pediatric patient. Pediatr Clin North Am. 2005 Aug;52(4):995-1027, vii-viii. Review."
            }, 
            {
                "PMID": "15174527", 
                "citation": "Breau LM, Camfield CS, McGrath PJ, Finley GA. Risk factors for pain in children with severe cognitive impairments. Dev Med Child Neurol. 2004 Jun;46(6):364-71."
            }, 
            {
                "PMID": "12960651", 
                "citation": "Zangen T, Ciarla C, Zangen S, Di Lorenzo C, Flores AF, Cocjin J, Reddy SN, Rowhani A, Schwankovsky L, Hyman PE. Gastrointestinal motility and sensory abnormalities may contribute to food refusal in medically fragile toddlers. J Pediatr Gastroenterol Nutr. 2003 Sep;37(3):287-93."
            }, 
            {
                "PMID": "17272610", 
                "citation": "Hauer JM, Wical BS, Charnas L. Gabapentin successfully manages chronic unexplained irritability in children with severe neurologic impairment. Pediatrics. 2007 Feb;119(2):e519-22."
            }, 
            {
                "PMID": "11343050", 
                "citation": "Breau LM, Camfield C, McGrath PJ, Rosmus C, Finley GA. Measuring pain accurately in children with cognitive impairments: refinement of a caregiver scale. J Pediatr. 2001 May;138(5):721-7."
            }, 
            {
                "PMID": "12237214", 
                "citation": "Breau LM, McGrath PJ, Camfield CS, Finley GA. Psychometric properties of the non-communicating children's pain checklist-revised. Pain. 2002 Sep;99(1-2):349-57."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01675960"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Gillette Children's Specialty Healthcare", 
            "investigator_full_name": "Scott Schwantes, M.D.", 
            "investigator_title": "Pediatrician", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "We will attempt to identify gastrointestinal and sleep problems in neurologically impaired children with questionnaires given throughout the study.  We hypothesize that gastrointestinal symptoms (feeding intolerance and symptoms associated with gas and bowel movements) and disrupted sleep are frequently associated with chronic irritability and will improve with gabapentin.", 
            "measure": "Prevalence of associated gastrointestinal and sleep problems in neurologically impaired children and improvement using gabapentin.", 
            "safety_issue": "No", 
            "time_frame": "Compiled data reviewed at completion or withdrawal from study (3 months from beginning study)."
        }, 
        "source": "Gillette Children's Specialty Healthcare", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Scott Schwantes, M.D.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}